Abstract
Anemia is common in inflammatory bowel disease (IBD), with a prevalence ranging from 8.8% to 73.7%. This wide range reflects the definitions used and the populations studied. Although many patients are reported to be asymptomatic, systematic studies have shown anemia to have a significant impact on quality of life. Consequently treatment should be instituted early. The commonest cause of anemia in IBD is iron deficiency, predominantly related to gastrointestinal blood loss. Anemia of chronic disease often occurs concomitantly, due to cytokine-mediated impaired erythropoiesis and dysregulated iron metabolism. Oral iron is a simple and effective method for treating iron deficiency, but requires long courses of treatment. It is also theoretically implicated with worsening intestinal inflammation, via the production of toxic reactive oxygen species. Intravenous iron avoids these concerns, especially with the development of ferric carboxymaltose, which allow up to 1000mg to be given rapidly. In patients failing to respond to intravenous iron, the anemia of chronic disease is most likely to be causative. In this setting evidence suggests that additional erythropoietin therapy can be effective. Blood transfusions should be avoided as part of routine management and reserved for patients with substantial acute gastro-intestinal bleeding, where there is a risk of hemodynamic compromise. This article discusses the underlying physiology of anemia in IBD, and presents the current evidence supporting treatment options available.
Keywords: Inflammatory bowel disease, anemia, Crohn’s disease, ulcerative colitis, iron deficiency, anemia of chronic disease, hemoglobin
Current Drug Delivery
Title:What is the Optimal Treatment for Anemia in Inflammatory Bowel Disease?
Volume: 9 Issue: 4
Author(s): Alexandra J. Kent, Victoria J. Blackwell and Simon P.L. Travis
Affiliation:
Keywords: Inflammatory bowel disease, anemia, Crohn’s disease, ulcerative colitis, iron deficiency, anemia of chronic disease, hemoglobin
Abstract: Anemia is common in inflammatory bowel disease (IBD), with a prevalence ranging from 8.8% to 73.7%. This wide range reflects the definitions used and the populations studied. Although many patients are reported to be asymptomatic, systematic studies have shown anemia to have a significant impact on quality of life. Consequently treatment should be instituted early. The commonest cause of anemia in IBD is iron deficiency, predominantly related to gastrointestinal blood loss. Anemia of chronic disease often occurs concomitantly, due to cytokine-mediated impaired erythropoiesis and dysregulated iron metabolism. Oral iron is a simple and effective method for treating iron deficiency, but requires long courses of treatment. It is also theoretically implicated with worsening intestinal inflammation, via the production of toxic reactive oxygen species. Intravenous iron avoids these concerns, especially with the development of ferric carboxymaltose, which allow up to 1000mg to be given rapidly. In patients failing to respond to intravenous iron, the anemia of chronic disease is most likely to be causative. In this setting evidence suggests that additional erythropoietin therapy can be effective. Blood transfusions should be avoided as part of routine management and reserved for patients with substantial acute gastro-intestinal bleeding, where there is a risk of hemodynamic compromise. This article discusses the underlying physiology of anemia in IBD, and presents the current evidence supporting treatment options available.
Export Options
About this article
Cite this article as:
J. Kent Alexandra, J. Blackwell Victoria and P.L. Travis Simon, What is the Optimal Treatment for Anemia in Inflammatory Bowel Disease?, Current Drug Delivery 2012; 9 (4) . https://dx.doi.org/10.2174/156720112801323026
DOI https://dx.doi.org/10.2174/156720112801323026 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bacterial Cell Wall Compounds as Promising Targets of Antimicrobial Agents II. Immunological and Clinical Aspects
Current Drug Targets High Throughput Screening and Structure-Activity Relationship Study of Potential α2A-Adrenoceptor Agonists by LANCETM cAMP Assay
Combinatorial Chemistry & High Throughput Screening The Phospholipase A2 Homologues of Snake Venoms: Biological Activities and Their Possible Adaptive Roles
Protein & Peptide Letters Thyroid Hormones and Cardiovascular System: From Bench to Bedside
Current Drug Therapy Tako-tsubo Cardiomyopathy: A Review of the Literature
Current Cardiology Reviews Pharmacological manipulation of peripheral vascular resistance in special clinical situations after pediatric cardiac surgery
Current Vascular Pharmacology Neuroprotection and Regeneration Strategies for Spinal Cord Repair
Current Pharmaceutical Design Genetically Engineered Elastin-based Biomaterials for Biomedical Applications
Current Medicinal Chemistry Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
Current Clinical Pharmacology An Insight into the Therapeutic Potential of Major Coffee Components
Current Drug Metabolism Treating Cancer and No-Cancer Pain in Older and Oldest Old Patients
Current Pharmaceutical Design Role of CGRP-Receptor Component Protein (RCP) in CLR/RAMP Function
Current Protein & Peptide Science Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia
Current Drug Therapy Ghrelin, A Novel Peptide Hormone in the Regulation of Energy Balance and Cardiovascular Function
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy and Cardiovascular Autonomic Neuropathy
Current Diabetes Reviews Review of Vital Signs Monitoring Systems – Patient’s Acceptability, Issues and Challenges
Neuroscience and Biomedical Engineering (Discontinued) Impact of Aging on the Angiogenic Potential of the Myocardium: Implications for Angiogenic Therapies with Emphasis on Sirtuin Agonists
Recent Patents on Cardiovascular Drug Discovery Propofol: Therapeutic Indications and Side-Effects
Current Pharmaceutical Design Nitric Oxide: News from Stem Cells to Platelets
Current Medicinal Chemistry Hydrophilic Dual Vitamin E-Like Antioxidants as Modulators of Inflammatory Response in Low-Flow States and Impaired Wound Healing
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents